CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
ErbB/HER 家族在肿瘤免疫学中的治疗进展与机制
英文原题：ErbB/HER family in cancer immunology: therapeutic advances and mechanisms.
查看英文原题
ErbB/HER family in cancer immunology: therapeutic advances and mechanisms.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
ErbB/HER 家族在肿瘤进展和免疫反应中具有关键作用，为癌症药物发现提供了有前景的靶点。特别是，以酪氨酸激酶抑制剂（TKIs）、单克隆/双特异性抗体（mAbs/BsAbs）和抗体-药物偶联物（ADCs）形式出现的 ErbB/HER 靶向治疗药物，已成为有效的治疗选择，通过提高治疗疗效、降低耐药性和降低全身毒性来实现优异的临床结果。多种 ErbB/HER 靶向治疗药物已在全球范围内用于众多临床试验，并获得美国食品药品监督管理局（FDA）批准。
此外，针对 ErbB/HER 家族成员的联合治疗与免疫治疗和化疗相结合，可增强治疗效果。在这篇综述中，我们重点介绍了靶向 ErbB/HER 家族成员的单一和联合抗癌治疗的最新进展，强调了它们作为变革性治疗策略的潜力。
我们还讨论了单一和联合 ErbB/HER 靶向药物设计与开发工作在结构、机制、选择性和疗效方面的最新进展，揭示了它们改善癌症治疗的潜力。
展开英文摘要原文
The ErbB/HER family has a crucial role in tumor progression and immune responses, offering promising targets for cancer drug discovery. In particular, ErbB/HER-targeted therapeutic agents, in the forms of tyrosine kinase inhibitors (TKIs), monoclonal/bispecific antibodies (mAbs/BsAbs), and antibody-drug conjugates (ADCs), have emerged as effective therapeutic options to achieve excellent clinical outcomes by improving treatment efficacy, reducing drug resistance, and lowering systemic toxicity.
Multiple ErbB/HER-targeted therapeutic agents have been used globally for numerous clinical trials, with US Food and Drug Administration (FDA) approval.
Furthermore, combination therapy targeting ErbB/HER family members with immunotherapy and chemotherapy enhances therapeutic effects. In this review, we highlight recent advances in single and combined anti-cancer therapeutics targeting ErbB/HER family members, underscoring their potential as transformative treatment strategies.
We also discuss recent advances in the structure, mechanism, selectivity, and efficacy of single and combined ErbB/HER-targeted drug design and development efforts, shedding light on their potential to improve cancer treatment.
论文信息
- 作者
- Yin L、Zhang H、Shang Y、Wu S、Jin T
- 第一作者单位
- Center of Disease Immunity and Intervention, College of Medicine, Lishui University, Lishui 323000, China; College of Medicine, University of Florida, Gainesville, FL 32608, USA; Division of Infectious Diseases and Geographic Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Laboratory of Structural Immunology, Key Laboratory of Immune Response and Immunotherapy, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027 China; Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, Anhui, China.China
- 通讯作者单位
- Center of Disease Immunity and Intervention, College of Medicine, Lishui University, Lishui 323000, China; Laboratory of Structural Immunology, Key Laboratory of Immune Response and Immunotherapy, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027 China; Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, Anhui, China; Anhui Genebiol Biotech. Ltd, Hefei 230000, China; Biomedical Sciences and Health Laboratory of Anhui Province, University of Science & Technology of China, Hefei 230027, China; Clinical Research Hospital of Chinese Academy of Sciences (Hefei), University of Science and Technology of China, Hefei 230001, China. Electronic address: jint@ustc.edu.cn.China
- 文献类型
- 综述
- 期刊
- Drug discovery today2025 Sep
- 原文标识
- PubMed 40714206 · DOI 10.1016/j.drudis.2025.104436